Company’s 36-month beta value is 1.41.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NUVB is 226.88M, and currently, short sellers hold a 13.58% ratio of that floaft. The average trading volume of NUVB on April 29, 2025 was 2.70M shares.
NUVB) stock’s latest price update
The stock price of Nuvation Bio Inc (NYSE: NUVB) has dropped by -0.23 compared to previous close of 2.16. Despite this, the company has seen a gain of 4.61% in its stock price over the last five trading days. businesswire.com reported 2025-04-22 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib’s New Drug Application with a Pr.
NUVB’s Market Performance
Nuvation Bio Inc (NUVB) has experienced a 4.61% rise in stock performance for the past week, with a 18.41% rise in the past month, and a -12.04% drop in the past quarter. The volatility ratio for the week is 5.56%, and the volatility levels for the past 30 days are at 8.89% for NUVB. The simple moving average for the past 20 days is 12.14% for NUVB’s stock, with a -15.49% simple moving average for the past 200 days.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Citizens JMP repeating the rating for NUVB by listing it as a “Mkt Outperform.” The predicted price for NUVB in the upcoming period, according to Citizens JMP is $6 based on the research report published on April 23, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $10, previously predicting the price at $1.40. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 27th, 2024.
BTIG Research gave a rating of “Buy” to NUVB, setting the target price at $5 in the report published on March 26th of the previous year.
NUVB Trading at 8.98% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.72% of loss for the given period.
Volatility was left at 8.89%, however, over the last 30 days, the volatility rate increased by 5.56%, as shares surge +21.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.51% lower at present.
During the last 5 trading sessions, NUVB rose by +4.13%, which changed the moving average for the period of 200-days by -35.78% in comparison to the 20-day moving average, which settled at $1.92. In addition, Nuvation Bio Inc saw -18.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUVB starting from Hung David, who purchase 300,000 shares at the price of $1.62 back on Apr 07 ’25. After this action, Hung David now owns 58,781,054 shares of Nuvation Bio Inc, valued at $487,500 using the latest closing price.
Hung David, the PRESIDENT AND CEO of Nuvation Bio Inc, purchase 200,000 shares at $1.66 during a trade that took place back on Apr 04 ’25, which means that Hung David is holding 58,481,054 shares at $332,720 based on the most recent closing price.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -21.28 for the present operating margin
- 0.06 for the gross margin
The net margin for Nuvation Bio Inc stands at -72.14. The total capital return value is set at -0.35. Equity return is now at value -106.27, with -97.74 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -14.63. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -491.37.
Currently, EBITDA for the company is -566.91 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 89.3. The receivables turnover for the company is 0.48for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.04.
Conclusion
In a nutshell, Nuvation Bio Inc (NUVB) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
